Navigation Links
Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools
Date:5/9/2012

BRANFORD, Connecticut and STATE COLLEGE, Pennsylvania, May 9, 2012 /PRNewswire/ --

454 Life Sciences, a Roche Company, and SoftGenetics announced today that the two firms have entered into a co-promotion agreement designed to provide users of 454 Sequencing Systems the broad range of next-generation sequencing data analysis options provided by SoftGenetics NextGENe® software.

NextGENe® software is a free standing biologist-friendly software multi-package that is fully compatibility with 454 Sequencing data for a wide variety of applications, including targeted amplicon resequencing, exome sequencing, transcriptome sequencing, forensic profiling and more. The software package provides additional options for users of 454 Sequencing Systems, in addition to the extensive GS Data Analysis Software suite provided with the platforms.

"This agreement permits both 454 and SoftGenetics the opportunity to more fully understand and address the rapidly changing needs of the NGS marketplace," states SoftGenetics co-founder John Fosnacht. "SoftGenetics welcomes the opportunity to work closely with our colleagues at 454 Life Sciences to provide our mutual customers with integrated sequencing and analysis systems that not only delivers the required quality and sensitivity, but also the efficiency needed in today's scientific and economic environments."

SoftGenetics offers 30-day trials and no cost web-based training on its genetic analysis software packages. Interested parties may request the software on the company website at http://www.softgenetics.com or via email at info@softgenetics.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in

Chugai Pharmaceutical, Japan. For more information: http://www.roche.com

About SoftGenetics

SoftGenetics, LLC specializes in the development of genetic analysis tools for both research and diagnostic applications. Hallmarks of SoftGenetics software tools are advanced technologies, providing exceptional accuracy, and sensitivity in an easy to use Windows® user interface.

For life science research only. Not for use in diagnostic procedures.

454, 454 LIFE SCIENCES, and 454 SEQUENCING, and are trademarks of Roche.

The name "SoftGenetics," the SoftGenetics logo, NextGENe, and the NextGENe Condensation Tool are trademarks or registered trademarks of SoftGenetics, LLC.

All other product names and trademarks are the property of their respective owners.


For further information please contact:
Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49-8856-604830
Email: burkhard.ziebolz@roche.com

454 Life Sciences Corporation, a Roche Company
Katie Montgomery
Phone: +1-203-871-2300
Email: katie.montgomery@roche.com

SoftGenetics
John Fosnacht
Phone: +1-814-237-9340
Email: john@softgenetics.com


'/>"/>
SOURCE Roche Diagnostics GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
2. 2 for 1: Simultaneous size and electrochemical measurement of nanomaterials
3. Kitty Castellini Wins Roche Diabetes Cares Diabetes Heroes Torchbearer Challenge
4. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
5. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
6. Electrochemistry controlled with a plasma electrode
7. Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing
8. Roche NimbleGen Announces New Pre-capture Multiplexing for Target Enrichment Technology in Sequencing
9. Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment
10. Roche Submits Acute Hepatitis B Test to FDA for Premarket Approval
11. China Agri-Business Acquired Management and Operation Rights of Shaanxi Qinfeng Agrochemical Inc. in Xian, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... WARSAW, Ind. , May 23, 2016 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the second quarter of 2016. ... on or about July 29, 2016 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
(Date:5/23/2016)... ... 23, 2016 , ... Foresight Institute , a leading ... for the 2015 Foresight Institute Feynman Prizes. , These prestigious prizes, named ... for experiment and the other for theory in nanotechnology. Prof. Markus J. Buehler, ...
(Date:5/20/2016)... ... 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural ... to treat the disease. Surviving Mesothelioma has just posted an article on the new ... institutions based their mesothelioma study on the fact the Manumycin A, a derivative of ...
(Date:5/19/2016)... , May 19, 2016 There ... fully recover given the relentless pressures in pricing and ... in the investors circle though - numerous opportunities are ... of today,s session, ActiveWallSt.com,s presents four names in this ... Vitae Pharmaceuticals Inc. (NASDAQ: VTAE ), Anthera ...
Breaking Biology Technology:
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
(Date:3/15/2016)... --> --> ... Research "Digital Door Lock Systems Market - Global Industry Analysis, ... global digital door lock systems market in terms of revenue ... forecast to grow at a CAGR of 31.8% during the ... enterprises (MSMEs) across the world and high industrial activity driving ...
Breaking Biology News(10 mins):